Utilization Pattern of Oral Hypoglycemic Agents for Diabetes Mellitus Type 2 Patients Attending Out-Patient Department at a University Hospital in New Delhi


Diabetes mellitus is the chronic disorder emerging as major world health problem which increases the rate of morbidity and mortality. The aim of the present study was to ascertain patterns of prescription of oral hypoglycemic agents to type 2 diabetic patients attending a university hospital, and to assess patient compliance. A prospective, observational and non comparative study was conducted in 200 established diabetes mellitus type 2 patients attending outpatient department at Majeedia Hospital, New Delhi, India. Prescriptions from registered patients were included in the study. Once the consultation by the physician was over, the prescriptions were reviewed and the patients were interviewed. The information was collected in an inhouse designed documentation proforma. In a pool of 200 type 2 diabetics, more than half were female (n=106, 53%). The mean age of the patients were found to be 50.4 ± 11.7 years and mean body mass index, 25.8 ± 4.4 kg/m2. A total of 432 oral hypoglycemic agents were prescribed to the patients. Highly significant number of patients were prescribed combination therapy, (n=143, 71.5%) as compared to monotherapy (n=57, 28.5%), p-value <0.0001. Biguanides were the most commonly prescribed class of oral hypoglycemic agents, followed by sulphonylureas, thiazolidinediones and α glucosidase inhibitors. Good compliance was seen in only 77.5% of the patients. Metformin was found to be the most commonly prescribed medicine.

Share and Cite:

Alam, M. , Aqil, M. , Shah Qadry, S. , Kapur, P. and Pillai, K. (2014) Utilization Pattern of Oral Hypoglycemic Agents for Diabetes Mellitus Type 2 Patients Attending Out-Patient Department at a University Hospital in New Delhi. Pharmacology & Pharmacy, 5, 636-645. doi: 10.4236/pp.2014.57073.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ahmed, A.M. (2002) History of Diabetes Mellitus. Saudi Medical Journal, 23, 373-378.
[2] Olokoba, A.B., Obateru, O.A. and Olokoba, L.B. (2012) Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 27, 269-273.
[3] Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C. and Holman, R.R. (2000) Association of Glycemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. British Medical Journal, 321, 405-412.
[4] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff Jr., D.C., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm Jr., R.H., Probstfield, J.L., Simons-Morton, D.G. and Friedewald, W.T. (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 358, 2545-2549.
[5] Advance Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., et al. (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 358, 2560-2572.
[6] Raz, I., Wilson, P.W., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A.K., Jermendy, G., Campaigne, B.N., Kerr, L., Milicevic, Z., et al. (2009) Effects of Prandial versus Fasting Glycaemia on Cardiovascular Outcomes in Type 2 Diabetes: The Heart 2D Trial. Diabetes Care, 32, 381-386.
[7] Davis, S.N. and Granner, D.K. (2001) Insulin, Oral Hypoglycemic Agents and the Pharmacology Endocrine Pancreas. In: Hardman, J.G. and Limbird, L.E., Eds., Goodman and Gilman’s T Pharmacological Basis of Therapeutics, McGraw Hill, New York, 1526-1531.
[8] Campbell, I.W. and Lebovitz, H. (2000) Fast Facts-Diabetes Mellitus; What Is Type 2 Diabetes? 2nd Edition, Health Press Ltd., Oxford, 18-25.
[9] Cox, E.M. and Elelman, D. (2009) Test for Screening and Diagnosis of Type 2 Diabetes. Clinical Diabetes, 4, 132-138.
[10] International Expert Committee (2009) International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care, 32, 1-8.
[11] Ahmann, A.J. and Riddle, M.C. (2002) Current Oral Agent for Type 2 Diabetes. Postgraduate Medicine, 111, 32-46.
[12] Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care, 27, 1047-1053.
[13] King, H., Aubert, R.E. and Herman, W.H. (1998) Global Burden of Diabetes, 1995-2025: Prevalence, Numerical Estimates and Projections. Diabetes Care, 21, 1414-1431.
[14] Pradeep, A.R. and Mohan, V. (2002) Changing Scenario of the Diabetes Epidemic. Implications for India. Indian Journal of Medical Research, 116, 121-132.
[15] Pradeep, A.R., Deepa, R. and Mohan, V. (2002) Epidemiology of Diabetes in India-Current Perspectives and Future Projections. Journal of Indian Medical Association, 100, 144-148.
[16] National Institute of Diabetes and Digestive and Kidney Diseases (2005) National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States. US Department of Health and Human Services. National Institute of Health, Bethesda.
[17] Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B., American Diabetes Association and European Association for Study of Diabetes (2006) Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-1972.
[18] Brown, A.F., Gregg, E.W., Stevens, M.R., Karter, A.J., Weinberger, M., Safford, M.M., Gary, T.L., Caputo, D.A., Waitzfelder, B. and Kim, C. (2005) Race, Ethnicity, Socioeconomic Position, and Quality of Care for Adults with Diabetes Enrolled in Managed Care: The Translating Research into Action for Diabetes (TRIAD) Study. Diabetes Care, 28, 2864-2870.
[19] Turner, R.C., Cull, C.A., Frighi, V. and Holman, R.R. (1999) Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. Journal of American Medical Association, 281, 2005-2012.
[20] Bakssas, I. and Lunde, P.K.M. (1986) National Drug Policies: The Need for Drug Utilization Studies. Trends in Pharmacological Sciences, 7, 331-334.
[21] Hansen, K.N., Mahata, M.C. and Parthasarthi, G. (2004) A Textbook of Clinical Pharmacy Practice: Essential Concepts and Skills. Orient Blackswan, Chennai, 362-375.
[22] Groop, I.C., Pelkonen, R., Koskimies, S., Bottazzo, G.F. and Doniach, D. (1986) Secondary Failure to Treatment with Oral Antidiabetic Agents in Non-Insulin Dependent Diabetes. Diabetes Care, 9, 129-133.
[23] Cumings, K.M., Kirscht, J.P., Becker, M.H. and Levin, N.W. (1984) Construct Validity of the Free Methods for Measuring Patient Compliance. Health Services Research, 19, 103-116.
[24] de Pablos-Velasco, P.L., Martínez-Martín, F.J., Molero, R., Rodríguez-Perez, F., García-Puente, I. and Caballero, A. (2005) Pattern of Prescription of Hypoglycemic Drugs in Gran Canaria (Canary Islands, Spain) and Estimation of the Prevalence of Diabetes Mellitus. Diabetes and Metabolism, 31, 457-462.
[25] Flier, J.S. and Maratos-Flier, E. (2005) Obesity. In: Kasper, D.L., Braunwald, E., Fauci, A.S., Hauser, S.L., Longo, D.L. and Jameson, J.L., Eds., Harrison’s Principles of Internal Medicine, 16th Edition, Vol. 1, Medical Publishing Division, McGraw-Hill, New York, 422-429.
[26] Hu, F.B., Manson, J.E., Stampfer, M.J., Colditz, G., Liu, S., Solomon, C.G. and Willett, W.C. (2001) Diet, Lifestyle, and the Risk of Type 2 Diabetes Mellitus in Women. New England Journal of Medicine, 345, 790-797.
[27] Sutharson, L., Hariharan, R.S. and Vamsadhara, C. (2003) Drug Utilization in Diabetology Outpatient Setting of a Tertiary Hospital. Indian Journal of Pharmacology, 35, 237-240.
[28] Das, P., Das, B.P., Rauniar, G.P., Roy, R.K. and Sharma, S.K. (2011) Drug Utilization Pattern and Effectiveness Analysis in Diabetes Mellitus at a Tertiary Care Centre in Eastern Nepal. Indian Journal of Physiology and Pharmacology, 55, 272-280.
[29] Desai, N.R., Shrank, W.H., Fischer, M.A., Avorn, J., Liberman, J.N., Schneeweiss, S., Pakes, J., Brennan, T.A. and Choudhry, N.K. (2012) Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications. American Journal of Medicine, 125, 302.e1-7.
[30] Boccuzzi, S.J., Wogen, J., Fox, J., Sung, J.C., Shah, A.B. and Kim, J. (2001) Utilization of Oral Hypoglycemic Agents in a Drug-Insured US Population. Diabetes Care, 24, 1411-1415.
[31] Chiang, C.W., Chiu, H.F., Chen, C.Y., Wu, H.L. and Yang, C.Y. (2006) Trends in the Use of Oral Antidiabetic Drugs by Outpatients in Taiwan: 1997-2003. Journal of Clinical Pharmacy and Therapeutics, 31, 73-82.
[32] Cusi, K. and Defronzo, R.A. (1998) Metformin: A Review of Its Metabolic Effects. Diabetes Review, 6, 89-131.
[33] Johnson, J.A., Majumdar, S.R., Simpson, S.H. and Toth, E.L. (2002) Decreased Mortality Associated with the Use of Metformin Compared with Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care, 25, 2244-2248.
[34] Cook, M.N., Girman, C.J., Stein, P.P., Alexander, C.M. and Holman, R.R. (2005) Glycemic Control Continues to Deteriorate after Sulfonylureas Are Added to Metformin among Patients with Type 2 Diabetes. Diabetes Care, 28, 995-1000.
[35] Laakso, M. and Letho, S. (1997) Epidemiology of Macrovascular Disease in Diabetes. Diabetes Reviews, 5, 294-315.
[36] Paes, A.H., Bakker, A. and Soe-Agnie, C.J. (1997) Impact of Dosage Frequency on Patient Compliance. Diabetes Care, 20, 1512-1517.
[37] Donnan, P.T., MacDonald, T.M. and Morris, A.D. (2002) Adherence to Prescribed Oral Hypoglycemic Medications in a Population of Patients with Type 2 Diabetes: A Retrospective Cohort Study. Diabetic Medicine, 19, 279-284.
[38] Brown, J.B., Nichols, G.A., Glauber, H.S. and Bakst, A. (1999) Ten-Year Follow-Up of Antidiabetic Drug Use, Nonadherence and Mortality in a Defined Population with Type 2 Diabetes Mellitus. Clinical Therapeutics, 21, 1045-1057. http://dx.doi.org/10.1016/S0149-2918(99)80023-X
[39] Ansari, K.U., Singh, S. and Pandey, R.C. (1998) Evaluation of Prescribing Pattern of Doctors for Rational Medicine Therapy. Indian Journal of Pharmacology, 30, 43-46.
[40] Upadhyay, D.K., Palaian, S., Prasad, R.S., Mishra, P. and Sah, A.K. (2007) Prescribing Pattern in Diabetic Outpatients in a Tertiary Care Teaching Hospital in Nepal. Journal of Clinical and Diagnostic Research, 3, 248-255.
[41] Eurich, D.T., Simpson, S.H., Majumdar, S.R. and Johnson, J.A. (2005) Secondary Failure Rates Associated with Metformin and Sulfonylurea Therapy for Type 2 Diabetes. Pharmacotherapy, 25, 810-816.
[42] Polonsky, K.S., Sturis, J. and Bell, G.I. (1996) Non-Insulin-Dependent Diabetes Mellitus—A Genetically Programmed Failure of the β-Cell to Compensate for Insulin Resistance. New England Journal of Medicine, 334, 777-783.
[43] Mirouze, J. and Augustin-Pascalis, I. (1988) Secondary Failure of Oral Antidiabetic and Dietetic Therapy in Non-InsulinDependent Diabetes Mellitus. Remission through Short Sessions of Continuous Intravenous Insulin Infusion. Diabetes Research and Clinical Practice, 4, 41-46.
[44] Bener, A., Zirie, M., Daghash, M.H., Al-Hamaq, A.O.A.A., Daradkeh, G. and Rikabi, A. (2007) Lipids, Lipoprotein (a) Profile and HbA1c among Arabian Type 2 Diabetic Patients. Biomedical Research, 18, 97-102.
[45] Schorr, U., Blaschke, K., Turan, S., Distler, A. and Sharma, A.M. (1998) Relationship between Angiotensinogen, Leptin and Blood Pressure Levels in Young Normotensive Men. Journal of Hypertension, 16, 1475-1480.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.